Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

NCT ID: NCT02477865

Last Updated: 2017-01-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 406 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-23
• Study Completion Date: 2017-02-28

Brief Summary

This is a phase III, multicenter, randomized, double-blind, placebo-controlled study planning to include approximately 387 T2DM patients who have received at least 8 weeks of treatment with diet control and exercise； have not received any glucose-lowering agents within the 8 weeks prior to screening; and have inadequately controlled blood glucose.The subjects would receive PEX168 or placebo monotherapy for 52weeks in total.

Detailed Description

This study consists of 4 periods： Period 1：Up to 3 weeks of screening period. Period 2：A 4-week PEX168 dummy run-in period. Period 3：A 52-week treatment period (including a 24-week core treatment period and a 28-week extended treatment period).

Period 4: A 4-week safety follow-up period. This study will last for approximately 63 weeks, including up to approximately 60 clinic visits.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

PEX168(100µg)

PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.

Group Type: EXPERIMENTAL

PEX168(100µg)

Intervention Type: DRUG

100µg,Subcutaneous injection,once a week. continued for 52 weeks

PEX168(200µg)

PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.

Group Type: EXPERIMENTAL

PEX168(200µg)

Intervention Type: DRUG

200µg,Subcutaneous injection,once a week. continued for 52 weeks

Placebo

Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.

Interventions

PEX168(100µg)

100µg,Subcutaneous injection,once a week. continued for 52 weeks

Intervention Type: DRUG

PEX168(200µg)

200µg,Subcutaneous injection,once a week. continued for 52 weeks

Intervention Type: DRUG

Placebo

0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.

Intervention Type: DRUG

Other Intervention Names

Polyethylene Glycol Loxenatide; Polyethylene Glycol Loxenatide; Injection mimetic

Eligibility Criteria

Inclusion Criteria

1. Type 2 diabetes mellitus confirmed by the 1999 WHO criteria；

2. Men or women；

3. Age at signing the ICF≥18 years and ≤78 years；

4. Body mass index (BMI) 20-40 Kg/m2；

5. At least 8 weeks of treatment with diet control and exercise received prior to screening；

6. No glucose-lowering agents received within the 8 weeks prior to screening；

7. 7.5%≤HbA1c≤11.0% at screening（local or centralized test）； 7.0%≤HbA1c≤10.5% at randomization（centralized test），and FBG< 13.9 mmol/L（local test）；

8. Ability to understand the procedures and approach of this study, willingness to complete the study in strict compliance with the protocol and to voluntarily sign the ICF.

Exclusion Criteria

1. Investigator suspecting the subject of allergy to the study drug；

2. Use of any of the following medications or therapies prior to screening：

1. GLP-1 receptor agonists, GLP-1 analogues, DPP-4 inhibitors or any other incretin analogues.

2. Growth hormone therapy within the 6 months prior to screening；

3. History of drug abuse or alcohol abuse；

4. Participation in any clinical trial within the 3 months prior to screening；

5. Prolonged intravenous, oral or intraarticular treatment with corticosteroids within the 2 months prior to screening;

6. Use of any weight control agents or surgeries within the 2 months prior to screening;

7. Any medications used prior to screening that at the investigator's discretion may confound the interpretation of the efficacy or safety data；

3. History or evidence of any of the following conditions prior to screening：

1. Type 1 diabetes mellitus, single gene mutation DM, DM associated with pancreatic injury，or secondary DM；

2. History of hypertension with SBP>160 mmHg and/or DBP>100 mmHg；

3. History of acute/chronic pancreatitis, history of symptomatic cholecystopathy;

4. History of myeloid C-cell carcinoma, history of multiple endocrine neoplasm （MEN） 2A or 2B syndrome, or related familiar history；

5. Gastric emptying disorders, severe chronic gastrointestinal disorders;

6. History of severe hypoglycemia, unconsciousness or severe hypoglycemia history；

7. Significant hematological disorders, or any diseases；

8. Severe diabetic complications that in the opinion of the investigator make the subject not suitable to participate in this study；

9. Tumors of any organ or system that not been treated within the 5 years prior to screening；

10. Coronary angioplasty, coronary stenting, coronary artery bypass, uncompensated heart failure （NYHA Class III or IV）, within the 6 months prior to screening；

11. Acute metabolic complications within the 6 months prior to screening；

12. Thyroid dysfunction within the 6 months prior to screening；

13. Blood lipid disorders within the 6 months prior to screening；

14. Any severe trauma or severe infection within the 1 month prior to screening；

4. Laboratory indicators meeting any of the following criteria prior to screening：

1. ALT>2.5×ULN and/or AST>2.5×ULN and/or total bilirubin>2.5×ULN；

2. Hemoglobin≤100 g/L；

3. Serum creatinine>1.5×UNL and eGFR < 45 ml/min/1.73 m2； eGFR is calculated as：186.3 ×[（Serum Creatinine（mmol/L）/88.4）]-1.154 × [Age (years)]- 0.203 × 1.223 × 0.742 （Females） or ×1（Males）

4. Serum thyroid-stimulating hormone（TSH） out of the reference range that is assessed as clinically significant by the investigator;

5. Fasting TGL>5.64 mmol/L（500 mg/dl）；

6. Blood amylase and urine amylase>ULN that is assessed as clinically significant by the investigator；

7. Any clinically significant laboratory abnormalities；

5. Clinically significant 12-lead ECG abnormalities；

6. Blood donation or loss≥400 mL，or receipt of blood donation within the 4 weeks prior to screening；

7. Pregnant or lactating women, or men or women of child-bearing potential not willing to take contraceptive measures during the study；

8. Any other conditions of the subject that at the investigator's discretion may compound the interpretation of the efficacy or safety data.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 78 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wenying Yang, MD

Role: PRINCIPAL_INVESTIGATOR

China-Japan Friendship Hospital

Other Identifiers

PEX168-301

Identifier Type: -

Identifier Source: org_study_id